Skip to main content

Advertisement

SpringerLink
Log in

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy

  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

We conducted this study among HIV-infected injection drug users to determine the effect of self-reported alcohol use and prior incarceration at the time of initiating antiretroviral therapy on subsequent HIV-1 RNA suppression. We examined the demographics, recent incarceration history, and drug and alcohol use history from the Vancouver Injection Drug User Study (VIDUS) questionnaire closest to the date of initiating antiretroviral therapy. We linked these data to the HIV/AIDS Drug Treatment Program. There were 234 VIDUS participants who accessed antiretroviral therapy through the Drug Treatment Program from August 1, 1996, to July 31, 2001. In terms of illicit drug use, 196 (84%) reported injecting heroin and cocaine at the time of initiating antiretroviral therapy. Multiple logistic regression revealed that in the 6 months prior to initiating antiretroviral therapy, alcohol use (adjusted odds ratio [AOR] 0.32; 95% CI 0.13–0.81) and incarceration (AOR 0.22; 95% CI 0.09–0.58) were independently associated with lower odds of HIV-1 RNA suppression. Factors positively associated with HIV-1 RNA suppression included: adherence (AOR 1.27; 95% CI 1.06–1.51); lower baseline HIV-1 RNA (AOR 1.30: 95% CI 1.01–1.66); highly active antiretroviral therapy (AOR 4.10; 95% CI 1.56–10.6); months on therapy (AOR 1.1; 95% CI 1.06–1.14). Among HIV-infected injection drug users who were on antiretroviral therapy, any alcohol use and incarceration in the 6 months prior to initiating antiretroviral therapy were negatively associated with achieving HIV-1 RNA suppression. In addition to addition treatment for active heroin and cocaine use, the identification and treatment of alcohol problems should be supported in this setting. As well, increased outreach to HIV-infected drug users recently released from prison to ensure continuity of care needs to be further developed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquired Immune Defic Syndromes. 2001;27(3):251–259.

    CAS  Google Scholar 

  2. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–774.

    Article  PubMed  Google Scholar 

  3. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–381.

    Article  PubMed  Google Scholar 

  4. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34(4):511–518.

    Article  CAS  PubMed  Google Scholar 

  5. Maruschak LM. Bureau of Justice Statistics Bulletin: HIV in Prisons and Jails, 1999. Document NCJ 187456, 2001. Available at ojp.usdoj.gov/bjs/pub/hivpj99.pdf. Accessed November 11, 2003.

  6. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–65.

    Article  CAS  PubMed  Google Scholar 

  7. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–549.

    Article  CAS  PubMed  Google Scholar 

  8. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283(3): 381–390.

    Article  CAS  PubMed  Google Scholar 

  9. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001;15(3):423–424.

    Article  CAS  PubMed  Google Scholar 

  10. Low-Beer S, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response [letter]. J Acquir Immune Defic Syndr. 2000;23(4):360–361.

    CAS  PubMed  Google Scholar 

  11. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–1058.

    Article  PubMed  Google Scholar 

  12. Fabris P, Tositti G, Manfrin V, et al. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients. J Acquir Immune Defic Syndr. 2000;25(1):92–93.

    Article  CAS  PubMed  Google Scholar 

  13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80.

    Article  CAS  PubMed  Google Scholar 

  14. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J Stud Alcohol. 2002;63(2):179–186.

    PubMed  Google Scholar 

  15. Sanchez-Craig M, Wilkinson DA, Davila R. Empirically based guidelines for moderate drinking: 1-year results from 3 studies with problem drinkers. Am J Public Health. 1995;85(6):823–828.

    Article  CAS  PubMed  Google Scholar 

  16. Barbor TF, de la Fuente JR, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1992.

    Google Scholar 

  17. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83–88.

    Article  CAS  PubMed  Google Scholar 

  18. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3): 305–312.

    Article  PubMed  Google Scholar 

  19. Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31(6):1476–1481.

    Article  CAS  PubMed  Google Scholar 

  20. White MC, Mehrotra A, Menendez E, Estes M, Goldenson J, Tulsky JP. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. Int J STD AIDS. 2001;12(6):380–385.

    Article  CAS  PubMed  Google Scholar 

  21. Kim JY, Rich J, Zeiler S, et al. Successful community follow-up and reduced recidivism of HIV positive women prisoners. J Correctional Health Care. 1997;4:1–9.

    Google Scholar 

  22. Stein MD, Urdaneta ME, Clarke J, et al. Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. J Addictive Dis. 2000;19(1):85–94.

    Article  CAS  Google Scholar 

  23. Clarke SM, Mulcahy FM. Antiretroviral therapy for drug users. Int J STD AIDS. 2000; 11(10):627–631.

    Article  CAS  PubMed  Google Scholar 

  24. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–1715.

    Article  CAS  PubMed  Google Scholar 

  25. Turner BJ, Zhang D, Laine C, Pomerantz RJ, Cosler L, Hauck WW. Association of provider and patient characteristics with HIV-infected women’s antiretroviral therapy regimen. J Acquir Immune Defic Syndr. 2001;27(1):20–29.

    CAS  PubMed  Google Scholar 

  26. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26(2):195–205.

    Article  CAS  PubMed  Google Scholar 

  27. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13(8):957–962.

    Article  CAS  PubMed  Google Scholar 

  28. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy. 2000;20(1):93–94.

    Article  CAS  PubMed  Google Scholar 

  29. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51(3):213–217.

    Article  CAS  PubMed  Google Scholar 

  30. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27(2):153–160.

    CAS  PubMed  Google Scholar 

  31. Carrieri MP, Vlahov D, Dellamonica P, et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug Alcohol Depend 2000;60(1):51–54.

    Article  CAS  PubMed  Google Scholar 

  32. Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38(9):911–925.

    Article  CAS  PubMed  Google Scholar 

  33. Raboud JM, Rae S, Vella S, et al. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. J Acquir Immune Defic Syndr. 1999;22(3):260–266.

    CAS  PubMed  Google Scholar 

  34. Havlir D, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286(2):171–179.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of British Columbia, Room 620B-1081 Burrard Street, V6Z 1Y6, Vancouver, British Columbia, Canada

    Anita Palepu, Mark W. Tyndall, Kathy Li, Benita Yip, Michael V. O’Shaughnessy, Martin T. Schechter, Julio S. G. Montaner & Robert S. Hogg

Authors
  1. Anita Palepu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark W. Tyndall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathy Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benita Yip
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael V. O’Shaughnessy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin T. Schechter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julio S. G. Montaner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert S. Hogg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anita Palepu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palepu, A., Tyndall, M.W., Li, K. et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 80, 667–675 (2003). https://doi.org/10.1093/jurban/jtg073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1093/jurban/jtg073

Keywords

Search

Navigation